CONTEXT: @entity1 Papillomaviruses (HPV) infect epithelial cells of the skin and mucosae. Mucosal high-risk HPV types (mainly @entity1799 and 18) are involved in the development of @entity5 , one of the most common @entity5 in young @entity1 . @entity281 is usually asymptomatic and clears spontaneously, but 10 - 15 % of high-risk @entity281 are persistent and increase the risk of precancerous and cancerous lesions of the cervix. Two HPV vaccines have been licensed to provide protection against @entity5 . OBJECTIVES: To report the different aspects of @entity281 in order to improve the understanding of the particular problems of HPV vaccination and to review the most recent findings related to HPV vaccines, particularly regarding the protective efficacy of vaccines and the roles of adjuvants and immune response in protection. METHODS: Articles were selected from the PubMed database (National Library of Medicine- National Institute of Health) with the following Keywords "HPV", "Prevention", "HPV vaccines", "Immune response", "Antibody". Abstracts of oral presentations from international meetings were also selected for the more recent findings. a critical analysis of the majority of papers published was undertaken and relevant information summarized. RESULTS: Virus-like particle production by expressing the major protein of the HPV capsid was carried out in the early 90's, leading to the recent development of two HPV vaccines. These vaccines are now licensed in many countries and have been demonstrated to be highly immunogenic. In subjects that are non-infected at the time of vaccination, HPV vaccines are highly effective in preventing persistent @entity1799 - 18 @entity281 (90 %) and precursors lesions of @entity5 associated with these two HPV types (close to 100 %). Clinical trials have also confirmed that HPV vaccines are well tolerated by recipients. CONCLUSIONS: The present paper is a detailed review published in French on HPV vaccines, their efficacy in the prevention of @entity281 and unresolved questions regarding the use of HPV vaccines. This report also includes biological and immunological information to improve the understanding of HPV vaccination.

[HPV immunization for the prevention of XXXX ].

@entity1 :: ('9606', 'Species') :: ['women', 'Human'] @entity281 :: ('MESH:D007239', 'Disease') :: ['HPV infection', 'infections', 'HPV infections'] @entity1799 :: ('333760', 'Species') :: ['HPV 16'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cervical cancer']
@entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']
